Načítá se...
Comparing drug safety of hepatitis C therapies using post-market data
BACKGROUND: Hepatitis C affects about 3 % of the world’s population. In the United States, about 3.5 million have chronic hepatitis C, and it is the leading cause of liver cancer and the most common indication for liver transplantation. In the last decades, new advances in therapy have substantially...
Uloženo v:
| Vydáno v: | BMC Med Inform Decis Mak |
|---|---|
| Hlavní autoři: | , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BioMed Central
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6686214/ https://ncbi.nlm.nih.gov/pubmed/31391106 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12911-019-0860-6 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|